[HTML][HTML] Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease
A Chait, LJ Den Hartigh - Frontiers in cardiovascular medicine, 2020 - frontiersin.org
Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …
several types of adipose tissue have been identified, namely white, brown, and beige, that …
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial
HW Rodbard, J Rosenstock, LH Canani… - Diabetes …, 2019 - Am Diabetes Assoc
OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …
[HTML][HTML] Empagliflozin and progression of kidney disease in type 2 diabetes
Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized …
GC Fernandes, A Fernandes, R Cardoso, J Penalver… - Heart Rhythm, 2021 - Elsevier
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …
SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
Background The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in
addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 …
addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 …
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Aims We previously reported that in the EMPA-REG OUTCOME® trial, empagliflozin added
to standard of care reduced the risk of 3-point major adverse cardiovascular events …
to standard of care reduced the risk of 3-point major adverse cardiovascular events …
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …